# TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

> **NCT02065362** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 14 (estimated)

## Conditions studied

- EBV-positive Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** DNR.NPC-specific T cells
- **BIOLOGICAL:** DNR.NPC-specific T cells + cyclophosphamide + fludarabine

## Key facts

- **NCT ID:** NCT02065362
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2017-03
- **Final completion:** 2033-02
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02065362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02065362, "TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02065362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*